Results 11 to 20 of about 36,208 (215)

Impact of Lymphopenia Recovery After Chemoradiotherapy on Durvalumab Consolidation Therapy in Stage III NSCLC

JTO Clinical and Research Reports, 2023
Introduction: Durvalumab maintenance therapy after definitive concurrent chemoradiotherapy (CRT) is the standard treatment modality for stage III NSCLC. Although severe treatment-related lymphopenia (TRL) during CRT may impair the efficacy of subsequent ...
Tomoki Kuge, MD, Takayuki Shiroyama, MD, PhD, Akihiro Tamiya, MD, Motohiro Tamiya, MD, Masaki Kanazu, MD, Yuhei Kinehara, MD, PhD, Tsunehiro Tanaka, MD, Osamu Morimura, MD, PhD, Yoshihiko Taniguchi, MD, Toshie Niki, MD, PhD, Satoshi Tetsumoto, MD, PhD, Kazuhiko Hayashi, MD, PhD, Kazumi Nishino, MD, PhD, Izumi Nagatomo, MD, PhD, Atsushi Kumanogoh, MD, PhD   +14 more
doaj   +1 more source

Prospective analysis of factors precluding the initiation of durvalumab from an interim analysis of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study)

Therapeutic Advances in Medical Oncology, 2022
Background: The standard of care for unresectable, locally advanced non-small cell lung cancer (LA-NSCLC) is chemoradiotherapy (CRT) followed by durvalumab, based on the PACIFIC trial. Disease progression and pneumonitis were reported as the main reasons
Shigeru Tanzawa, Tomonori Makiguchi, Sadatomo Tasaka, Megumi Inaba, Ryosuke Ochiai, Junya Nakamura, Koji Inoue, Takayuki Kishikawa, Masanao Nakashima, Keiichi Fujiwara, Tadashi Kohyama, Hiroo Ishida, Shoichi Kuyama, Naoki Miyazawa, Tomomi Nakamura, Hiroshi Miyawaki, Naohiro Oda, Nobuhisa Ishikawa, Ryotaro Morinaga, Kei Kusaka, Yosuke Miyamoto, Toshihide Yokoyama, Chiaki Matsumoto, Takeshi Tsuda, Sunao Ushijima, Kazuhiko Shibata, Takuo Shibayama, Akihiro Bessho, Kyoichi Kaira, Toshihiro Misumi, Kenshiro Shiraishi, Noriyuki Matsutani, Nobuhiko Seki   +32 more
doaj   +1 more source

Use of durvalumab in stage III non‐small‐cell lung cancer based on eligibility for the PACIFIC study

Thoracic Cancer, 2023
Background Durvalumab following concurrent chemoradiotherapy is standard treatment for unresectable stage III non‐small‐cell lung cancer based on the results of the PACIFIC trial.
Emma Boys, Bo Gao, Rina Hui, Inês daSilva, Eric Hau, Harriet Gee, Adnan Nagrial   +6 more
doaj   +1 more source

Unresectable stage III non-small cell lung cancer: could durvalumab be safe and effective in real-life clinical scenarios? Results of a single-center experience

Frontiers in Oncology, 2023
IntroductionThe standard of care for patients with unresectable stage III non-small cell lung cancer (NSCLC) is chemoradiotherapy (CRT) followed by consolidation durvalumab as shown in the PACIFIC trial.
Paolo Borghetti, Giulia Volpi, Giorgio Facheris, Gianluca Cossali, Eneida Mataj, Salvatore La Mattina, Navdeep Singh, Jessica Imbrescia, Marco Lorenzo Bonù, Davide Tomasini, Paola Vitali, Diana Greco, Michela Bezzi, Flavia Melotti, Mauro Benvenuti, Andrea Borghesi, Salvatore Grisanti, Michela Buglione di Monale e Bastia   +17 more
doaj   +1 more source

Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab

Cancer Medicine, 2020
Introduction Durvalumab after concurrent chemoradiation (cCRT) is now standard of care for unresected stage III non–small cell lung cancer (NSCLC). However, there is limited data on radiation pneumonitis (RP) with this regimen.
Narek Shaverdian, Maria Thor, Annemarie F. Shepherd, Michael D. Offin, Andrew Jackson, Abraham J. Wu, Daphna Y. Gelblum, Ellen D. Yorke, Charles B. Simone II, Jamie E. Chaft, Matthew D. Hellmann, Daniel R. Gomez, Andreas Rimner, Joseph O. Deasy   +13 more
doaj   +1 more source

Longitudinal changes of blood parameters and weight in inoperable stage III NSCLC patients treated with concurrent chemoradiotherapy followed by maintenance treatment with durvalumab

BMC Cancer, 2022
Background Investigating dynamic changes in blood-parameters and weight in patients with locally advanced non-small cell lung cancer (NSCLC) receiving durvalumab maintenance therapy after chemoradiotherapy (cCRT).
J. Guggenberger, S. Kenndoff, J. Taugner, L. Käsmann, B. Flörsch, C. Belka, C. Eze, F. Manapov   +7 more
doaj   +1 more source

Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head‐and‐neck cancer

Cancer Medicine, 2022
Background Agents targeting the programmed cell death‐1 pathway have demonstrated encouraging activity across multiple solid tumor types. The dose expansion phase of this phase I study evaluated the safety, tolerability, and antitumor activity of ...
Yuichiro Doki, Makoto Ueno, Chih‐Hung Hsu, Do‐Youn Oh, Keunchil Park, Noboru Yamamoto, Tatsuya Ioka, Hiroki Hara, Manabu Hayama, Masahiro Nii, Keiko Komuro, Mariko Sugimoto, Makoto Tahara   +12 more
doaj   +1 more source

Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity. [PDF]

, 2020
Although immunotherapies have achieved remarkable salutary effects among subgroups of advanced cancers, most patients do not respond. We comprehensively evaluated biomarkers associated with the "cancer-immunity cycle" in the pan-cancer setting in order ...
Dressman, Devin, Eskander, Ramez, Glenn, Sean T, Goodman, Aaron, Ikeda, Sadakatsu, Kato, Shumei, Kumaki, Yuichi, Kurzrock, Razelle, Lee, Suzanna, Lenzo, Felicia L, Morrison, Carl, Nikanjam, Mina, Okamura, Ryosuke, Papanicolau-Sengos, Antonios   +13 more
core   +1 more source

Cost-effectiveness analysis of durvalumab plus chemotherapy as first-line treatment for biliary tract cancer

Frontiers in Public Health, 2023
ObjectiveThe TOPAZ-1 trial reported a significant survival benefit of durvalumab in combination with chemotherapy for the first-line treatment of biliary tract cancer (BTC). However, no studies have evaluated the economics of this treatment option.
Zhuo-miao Ye, Zhe Xu, Huan Li, Qian Li
doaj   +1 more source

Predictive value of post‐treatment C‐reactive protein‐to‐albumin ratio in locally advanced non–small cell lung cancer patients receiving durvalumab after chemoradiotherapy

Thoracic Cancer, 2022
Backgrounds The PACIFIC trial established durvalumab consolidation therapy after concurrent chemoradiotherapy (CCRT) as the standard treatment for locally advanced non–small cell lung cancer (LA‐NSCLC).
Taisuke Araki, Kazunari Tateishi, Masamichi Komatsu, Kei Sonehara, Satoshi Wasamoto, Shigeru Koyama, Fumiaki Yoshiike, Mineyuki Hama, Kenichi Nishie, Daichi Kondo, Toshihiko Agatsuma, Akane Kato, Munetake Takata, Shintaro Kanda, Masayuki Hanaoka, Tomonobu Koizumi   +15 more
doaj   +1 more source